NEW YORK (GenomeWeb) – Waters has entered into an amendment of its credit agreement with JP Morgan Chase Bank.

In a document filed on Thursday with the US Securities and Exchange Commission, Waters said that the amendment would increase revolving commitments from $1.1 billion to $1.3 billion, extend the maturity of loans and other obligations under the agreement, and provide for certain changes in the interest rate margins and fees.

The firm said it plans to use future borrowings for general corporate purposes.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.